CSPC Pharmaceutical Group received clinical trial clearance from China’s National Medical Products Administration (NMPA) for JMT‑206, a weight‑management candidate intended for patients with obesity or overweight plus at least one weight‑related comorbidity. The green light enables CSPC to initiate human testing and position JMT‑206 within a competitive GLP‑1–dominated obesity market. The company will now launch Phase I safety and dose‑finding studies in China; regulators and investors will be watching endpoints and safety in the context of rapidly evolving standards for metabolic drugs. The clearance underscores continued global interest in new mechanisms and formulations for obesity treatment.